Immunosuppressive therapy in neurological diseases.
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004660:Encephalitis / Q000188:drug therapy; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007111:Immunity, Cellular / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology; D008213:Lymphocyte Activation; D008727:Methotrexate / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy; D009157:Myasthenia Gravis / Q000188:drug therapy; D009220:Myositis / Q000188:drug therapy / Q000276:immunology; D009443:Neuritis / Q000188:drug therapy; D011128:Polyradiculopathy / Q000188:drug therapy / Q000276:immunology; D011241:Prednisone / Q000627:therapeutic use; D014777:Virus Diseases / Q000188:drug therapy
D007166:Immunosuppressive Agents; D003561:Cytarabine; D003520:Cyclophosphamide; D000324:Adrenocorticotropic Hormone; D001379:Azathioprine; D011241:Prednisone; D006854:Hydrocortisone; D008727:Methotrexate